Drug glossary Immunotherapy

Serplulimab

A drug being studied in colorectal cancer trials. It appears in 21 clinical trials.

Intravenous PD-1

United States Investigational

European Union Investigational

Spain Not available

What it is

Serplulimab is a monoclonal antibody immunotherapy agent that targets the PD-1 (programmed death-1) receptor on T cells. In colorectal cancer treatment, it is used in combination regimens with chemotherapy, targeted therapies, and radiation therapy for both locally advanced and metastatic disease. The drug shows particular application in microsatellite stable (MSS) colorectal cancers, which typically respond poorly to single-agent immunotherapy. Clinical trials have evaluated serplulimab in neoadjuvant settings for locally advanced colon cancer and in multimodal treatment approaches for rectal cancer with oligometastases.

How it works

Serplulimab binds to the PD-1 receptor on activated T lymphocytes, blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2. This blockade prevents the inhibitory signals that normally suppress T cell activation, thereby enhancing the immune system's ability to recognize and attack cancer cells.

Molecular targets

PD-1

Common side effects

FatigueSkin rashDiarrheaDecreased appetiteNauseaHypothyroidismElevated liver enzymesPneumonitis

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.

Trials with this drug

8 recruiting

A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy NCT07604909 Recruiting Phase 2 China Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) NCT07150949 Recruiting Phase 2 China SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases NCT06850103 Recruiting Phase 2 China Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer NCT06521866 Recruiting Phase 2 China Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer NCT06368141 Recruiting Phase 2 China Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients NCT06280495 Recruiting Phase 2 China

See all 21 trials

Guides that may help

Written for patients and families, in plain language.

MSI-H / dMMR: what it means and why it changes treatmentMSI-H (high microsatellite instability) and dMMR (deficient mismatch repair) describe the same thing: a tumour that accumulates…Eating during chemotherapy: what the evidence supports and what it does notThere is no "anti-cancer diet" that improves the outcome of chemotherapy. What is proven is that losing weight and muscle during…Cancer-related fatigue: what actually helpsCancer-related fatigue is the most common symptom during and after treatment, and it is not fixed by sleeping more. Before…

See all guides →